CRISPR Therapeutics AG

NASDAQ Global Market
Back to all articles
Bullish +55

CRISPR Therapeutics Provides Business Update and Reports Second Quarter ...

📅 CRISPR Therapeutics reported Q2 2026 financial results and provided a business update on August 3, 2026.

✅ CASGEVY momentum continues with FDA approval extended to children as young as 2 years old for sickle cell disease and transfusion-dependent beta thalassemia.

🧬 Phase 1 clinical trials were initiated for CTX340 (refractory hypertension) and CTX460 (alpha-1 antitrypsin deficiency).

🤝 Vertex Pharmaceuticals leads global development and commercialization of CASGEVY under a 60/40 profit-sharing agreement.

💉 CRISPR Therapeutics is advancing in vivo liver editing programs using its proprietary SyNTase technology for cardiovascular indications.

🧬 Zugocabtagene geleucel (zugo-cel) advances as an allogeneic CAR T cell therapy for autoimmune diseases and oncology.

🩸 Collaboration with Sirius Therapeutics develops CTX611, a long-acting siRNA targeting coagulation factor XI.

Bullish Signals
  • CASGEVY demonstrates strong market momentum with regulatory expansion to include pediatric patients as young as two years old.
  • The company successfully initiated Phase 1 clinical trials for two new in vivo programs, CTX340 and CTX460, expanding its therapeutic reach.
  • Strategic collaborations with Vertex and Sirius Therapeutics provide a diversified pipeline spanning gene editing and siRNA technologies.
Full Analysis
CRISPR Therapeutics reported financial results and a business update for the second quarter ended June 30, 2026. CEO Samarth Kulkarni highlighted strong execution across the portfolio, noting continued momentum for CASGEVY following FDA approval for children as young as two years old. The company also expanded its in vivo pipeline by initiating Phase 1 clinical trials for CTX340 targeting refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency. The press release details the company's diversified portfolio, including its strategic collaboration with Vertex Pharmaceuticals for CASGEVY, where Vertex leads global development and commercialization while profits are shared on a 60/40 basis. CRISPR Therapeutics is advancing proprietary in vivo liver editing programs using its SyNTase technology to treat cardiovascular diseases like familial hypercholesterolemia and hypertension. Additionally, the company is developing Zugocabtagene geleucel (zugo-cel), an allogeneic CAR T cell therapy for autoimmune diseases and hematologic malignancies. A collaboration with Sirius Therapeutics focuses on siRNA-based programs, specifically CTX611, a long-acting inhibitor of coagulation factor XI intended to provide anticoagulant effects with reduced bleeding risk.